nujib helps traveling nurses book housing with security, travel with confidence, and stay with certainty.

WINTER GARDEN, Fla., January 31, 2023 (Newswire.com) - nujib is proud to announce its official launch for renters and traveling medical professionals in the Florida market.

nujib is where travel nurses and medical professionals look when they need furnished housing for short-term stays and is the only full-service platform for short-term stays that caters to medical travelers specifically. The platform allows the traveler to view properties in Florida, communicate with owners, book, and pay all from one easy-to-use app. nujib founder and CEO Michael Beers believes it is important that traveling professionals are empowered to "book with security, travel with confidence, and stay with certainty."

With a nujib user profile, traveling professionals can view hundreds of Florida properties with convenience and ease. Search criteria is easily inputted and is narrowed down by date, location, pet policy, and other amenities. Once a profile is created, you can stay up to date with messages and notifications, so you never miss the perfect stay.

Property owners' profiles allow for real-time notifications and requests, and the app is integrated to provide seamless communication and payment processing. Owners can rest comfortably, as Damage Protection Insurance and tenant screening are provided with no additional cost. 

Payment protection and security are at the forefront of nujib's mission. Every Florida property is screened through a national database where property owners provide verified ownership documentation, and payments are made through our secure payment gateway. Gone is the anxiety of making travel arrangements or renting your property - nujib is the future of short-term stays.

Create your nujib account today by visiting us at nujib.com.

###

Contact Information:
Amanda McCallister
Director of Accounts
[email protected]
863-204-2143

Cathrin Epps
Office Administrator
[email protected]
863-204-0959


Original Source: New Short-Term Housing Platform for Traveling Nurses

Comprehensive surgical program includes patient education, state-of-the-art robot-assisted surgical system, on-site physical therapy, and same-day discharge

LITHIA, Fla., January 31, 2023 (Newswire.com) - The recently opened OMG Surgery Center (OMGSC) is a fully equipped surgical center that has been designed specifically with their Total Joint Replacement Program in mind, including the design of two large OR suites and robot-assisted surgical system. This comprehensive program begins in the physician's office, where patients are fully educated on the entire surgery process and discuss post-operative recovery. The patients also attend a free educational class prior to surgery to review the procedure, how to prepare, and the necessary steps for success. If the patient elects to use the Robotic-Assisted surgical program, they will be required to get a specialized CT Scan, which is coordinated for them.

A nurse will call every patient the night before their surgery to ensure they are prepared for the procedure. Once at OMGSC, each patient is prepped for the procedure and will talk with the surgeon, anesthesiologist, and nurses. Once in the operating room, the team will utilize the state-of-the-art robotics and software programs to assist the surgeon with surgery. The physician has complete control over the robotic system; however, it assists with making very precise cuts. "The surgeons and staff have worked hard to develop, design and build not only a surgical center but a comprehensive program that helps with patient recovery from complex surgical procedures," said Dr. Jeff Watson, orthopaedic surgeon at the Orthopaedic Medical Group of Tampa Bay.

Before leaving, the patient will begin a short course of therapy, walk, and go up/down some steps to ensure comfort with the new hip/knee. All patients that receive a total joint replacement at OMGSC are sent home within hours of their procedure. Dr. Scott Goldsmith, CEO of the Orthopaedic Medical Group of Tampa Bay, noted, "Patients recover better sleeping in their own beds and prefer to be home with family after hip or knee replacement surgery, so we have designed a program from start to finish that helps them achieve a better outcome." Typically, they will be seen back in the physician's office two to four weeks after surgery. 

The team at OMGSC has performed over 80 total hip & knee joint surgeries in their first six months of operation. They will continue to grow their program in 2023 and look forward to seeing many patients walk out of the center with less long-lasting pain. 

If you would like to learn more about OMG Surgery Center, visit them at www.OMGSurgeryCenter.com or give them a call at 813-535-6647.

Contact Information:
Kevin Sando
Owner, VitalUP Marketing
[email protected]


Original Source: New OMG Surgery Center Offers Specialized Approach to Total Joint Replacement Surgery

Expansion Includes New Claims Data Analytics and Data Integration Hires

LOUISVILLE, Ky., January 31, 2023 (Newswire.com) - HSG Advisors, a national healthcare consulting firm, has expanded its consulting services and data analytics capabilities to address changing strategies for healthcare systems and hospitals as outpatient utilization trends continue to shift. HSG Advisors' Claims Data Analytics services are designed to provide key insights that inform strategic growth so organizations can better serve their markets and improve their bottom line.

This consulting service is distinguished with proprietary all-payer healthcare claims data and paired with healthcare business expertise. HSG Advisors' Claims Data Analytics service allows healthcare organizations to gain a more in-depth understanding of their competitors and the dynamics of their specific market to support organizational growth objectives. 

"Our expanded consulting services and data capabilities are designed to provide healthcare leaders with organization-specific, market-specific, and service-specific insights to develop customized strategies for success," says D.J. Sullivan, Managing Director, Claims Data Analytics at HSG Advisors.

HSG Advisors provides clients with proprietary data and publishes regular market share updates to support clients' markets and service line growth objectives. HSG Outpatient and Ambulatory Market Share, HSG Patient Flow, and HSG Patient Share of Care are updated quarterly and published on clients' custom HSG Dashboard to provide easy access to data insight. Data is published on a 5-month delay, always providing up-to-date insights and ROI measurement in strategic growth objectives.

As of November 2022, HSG Advisors has added new data views, groupings, and market share mappings for clients to access. These data sets include: 

• Technical v. Professional Claims Selector
• Patient Services v. Procedural Volumes Selector
• Trended Dashboard Groupings Rolling up Health System Entities Comprehensively
• Provider-Level Market Share Mapping

The company has slated several additional new service line categories for a February 2023 launch: 

• Gastroenterology (Colonoscopy, Endoscopy, ERCP)
• Updated Service Line Groupings
• Cardiology (Cardiac Rehab)
• Home Health & Preventative Evaluations E&Ms
• Allergy, Anesthesia, Drug Administration, Durable Medical Equipment, Hearing Services, Immunization Administration, Medical & Surgical Supplies, Orthotic & Prosthetic Devices, Transportation, and Vision Services
• Updated Provider Dashboard Specialties & Selection Based on Claims-Based Specialty and Provider Specialty Roll-up. Updated claims-based and provider-specialty data will have a significant impact on the accuracy of advanced practice provider specialties and physician sub-specializations.

As part of the consulting service expansion, HSG Advisors welcomes three new experts to its Claim Data Analytics practice. Michelle Sevilla, Claims Data Analytics Manager, joined in November 2022 to help client organizations fully utilize and integrate analytics into their organization's initiatives. She's also responsible for working with HSG Advisors leadership to develop, refine, and enhance the products and services they offer. Tanya Hoang, Data Integration Analyst, joined in January 2023, and helps develop strategies for utilizing data across all of HSG Advisors' offerings to maximize its benefits to clients. She partners with the Data Engineering and Data Analyst roles to streamline processes and optimize client delivery. Abhijith Nair, Senior Data Analyst, joined in January 2023 upon graduation from the University of Louisville's Masters of Science in Data Analytics program. These three new hires expand HSG Advisors' ability to provide both strategic guidance and tactical support to clients in its growing consultancy and help clients stay ahead of the curve on outpatient utilization trends in 2023 and beyond.

Contact Information:
Karolyn Raphael
PR for HSG Advisors
[email protected]
312-494-0422


Original Source: HSG Advisors Expands Consulting Services and Data Analytics Capabilities in Response to National Outpatient Utilization Trends

In the Digital Health and Startups category at the 2023 Consumer Electronics Show (CES), Eyenovia showcased its Microdose Array Print (MAP™) Technology, the first significant advancement in ocular drug delivery methods in over a century.

LAS VEGAS, January 31, 2023 (Newswire.com) - Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, showcased the Microdose Array Print (MAP™) Technology at CES 2023 in Las Vegas, Nevada, from Jan. 5-8. Eyenovia highlighted the technology and its human-centric approach to ocular drug delivery to over 115,000 attendees.

"CES 2023 is raising the bar for digital health innovation by bringing even more cutting-edge brands and technologies to the forefront," said Michael Rowe, CEO of Eyenovia. "We're honored to be among the impressive array of new innovations and brands taking center stage." 

The microdosing technology behind Optejet® prioritizes ease of use, appropriate dosing, and reducing wasted medication by administering one-fifth the volume of a solution compared to a traditional eyedropper. This method of drug delivery may reduce the risk of overdosing, which may lead to less adverse side effects and offers patients an easier, more precise way to dispense eye drop medications.

Eyenovia presented its latest human-centric innovations in the Digital Health and Startups category to an audience of over 4,700 media professionals and outlets. The 2023 Consumer Electronics Show brings together more than 3,200 exhibitors representing 173 countries, territories, and regions.

Eyenovia is creating an entire pipeline of advanced therapeutics based on its proprietary Microdose Array Print (MAP™) platform technology. The Optejet® dispenser is the technology underlying Eyenovia's research and development targeting progressive myopia, presbyopia and mydriasis.

"CES 2023 is a testament to the rapid expansion of the digital health market, with an abundance of new brands and innovations being unveiled," concluded Rowe. "Our team is excited about the positive feedback and excitement, and we're looking forward to the opportunity to bring Optejet® to the consumer market if it receives regulatory approval."

Optejet® has not been approved, cleared, or licensed by the U.S. Food and Drug Administration for any use, and it is not commercially available in the United States. 

About Eyenovia, Inc.

Eyenovia, Inc. is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAPTM) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit www.eyenovia.com. 

Forward-Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws. Eyenovia does not undertake any obligation to update any forward-looking statements.

Contact Information:
Buse Kayar
[email protected]

Norbert Lowe
Vice President, Commercial Operations
[email protected]
Related Images


Original Source: Eyenovia Showcases Microdose Array Print (MAP™) Technology at CES 2023 in Las Vegas

Healthcare analytics firm secures Series D financing to invest in continued growth

JACKSONVILLE, Fla., January 31, 2023 (Newswire.com) - Clearsense®, a PaaS company that partners with healthcare organizations to increase data value, governance, and transparency, announced their successful $50M Series D capital raise led by HealthQuest Capital. The raise brought the healthcare-dedicated investment group to Clearsense with the shared goal of improving trust in enterprise data and expanding data-driven operations within healthcare organizations. HealthQuest was joined by existing investors Health Catalyst Capital and UPMC Enterprises.

"This investment into our organization further strengthens our mission to unlock the full potential of healthcare data by delivering solutions that empower data confidence and enable data-driven decision-making to achieve better outcomes," said Gene Scheurer, CEO of Clearsense. "We're elated to begin a relationship with HealthQuest, which shares the same vision: Transforming healthcare." 

Along with the raise, Clearsense welcomes new board member, Anthony Williams, partner at HealthQuest. Mr. Williams brings over 22 years of industry experience and serves as a Board Director for HealthQuest portfolio companies Perspectum, ENT Specialty Partners, and 83bar. 

Mr. Williams commented, "We seek to partner with transformative companies that meaningfully improve patient outcomes and economics across the healthcare ecosystem. Clearsense's platform accomplishes both of these objectives by enabling hospitals and health systems to utilize their data as a valuable asset. We're excited to partner with the company as it continues its impressive growth trajectory."

Clearsense's focus includes elevating health outcomes through data-based solutions and a commitment to promoting data literacy within healthcare. With 2023 poised to be a huge growth year for Clearsense, this new funding will allow Clearsense to further invest in infrastructure, technology, and people to drive the expansion of the 1Clearsense Data Management Platform.

Piper Sandler served as the sole placement agent and financial advisor in the transaction. 

About HealthQuest Capital

Based in the San Francisco Bay Area, HealthQuest Capital is a growth capital firm investing in commercial-stage companies that are optimizing value in healthcare by improving outcomes and reducing costs. With more than $1.6 billion in capital under management, the firm focuses on fostering innovation across the healthcare spectrum, including medical technologies, diagnostics/tools, digital health, and innovative services. The HealthQuest team combines decades of successful investing experience with deep domain expertise in all aspects of the healthcare industry. For more information, visit www.healthquestcapital.com.

About Clearsense

Committed to leading transformation in healthcare, Clearsense® creates a data journey, all the way from numbers to key insight. Cloud-based, AI-enabled, and HITRUST-certified, the platform of data applications ensure data governance, implementation, and analytics are rapidly mainstreamed while remaining scalable and secure. Driving faster outcomes in clinical, financial, and operational environments, Clearsense is powering the innovation of tomorrow—right now. Learn more at Clearsense.com.

# # #

Contact Information:
Kate-Madonna Hindes
Director of Marketing
[email protected]
612-501-7986


Original Source: Clearsense Announces Success of $50M Capital Raise